Back to search results

NAL ER for Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough

This study is looking into whether NAL ER tablets can help reduce chronic cough in people with Idiopathic Pulmonary Fibrosis (IPF). IPF is a lung disease that causes scarring of the lungs. Researchers want to see if NAL ER is safe and effective for this type of cough. You might be able to join if you are 40 years or older, have been diagnosed with IPF by a doctor, and have had a chronic cough for at least 8 weeks. The main goal is to see how much your 24-hour cough frequency changes after 26 weeks of treatment. The study is currently unclear on its recruitment status and plans to enroll about 306 participants.

Study design
This interventional study will compare NAL ER oral tablets to a placebo (an inactive pill) in about 306 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your cough frequency will be measured at the beginning of the study and again at Week 26.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07671911

Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets

Recruiting
PHASE3Ages 40+InterventionalTreatment
Trevi Therapeutics
~306 participants
Updated 2026-09-14 on ClinicalTrials.gov
What's tested:NAL ERPlacebo

At a glance

Recruiting sites
19 of 19 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Relative Change from Baseline in 24-hour Cough Frequency at Week 26
Measured over Baseline, Week 26

Conditions

Idiopathic Pulmonary Fibrosis

Explore related trials

Idiopathic Pulmonary Fibrosis

NCT07671911

Where you'd take part

This study runs at 19 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Anmed Medical Center

    Anderson, South Carolinano site contact published

    Recruiting

  • Clinical Research and Associates, Inc.

    Miami, Floridano site contact published

    Recruiting

  • Clinical Research Associates of Central, PA, LLC

    DuBois, Pennsylvaniano site contact published

    Recruiting

  • Clinical Research of Gastonia (CRG)

    Gastonia, North Carolinano site contact published

    Recruiting

  • Clinical Research Specialists, Llc - Kissimmee

    Kissimmee, Floridano site contact published

    Recruiting

  • Coastal Pulmonary & Critical Care, PLC

    St. Petersburg, Floridano site contact published

    Recruiting

  • Critical Care Pulmonary and Sleep Associates (Ccpsa) - West Clinic

    Lakewood, Coloradono site contact published

    Recruiting

  • El Paso Pulmonary Association, PA

    El Paso, Texasno site contact published

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Chief Development Officer · STUDY_DIRECTOR · Trevi Therapeutics

Who to contact

Paula Buckley
[email protected]
(203) 304-2499
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosis of IPF as determined by the Investigator based on American Thoracic Society (ATS)/European Respiratory Society (ERS)/Japanese Respiratory Society (JRS)/Latin American Thoracic Society (ALAT) clinical practice guidelines.
Chronic cough for ≥8 weeks prior to Screening.
PGI-Severity Score ≥ 2 at Screening.
Forced vital capacity (FVC) ≥40 percent (%) of predicted at Screening.
Diffusing capacity for carbon monoxide (DLCO) ≥25% of predicted during Screening or within 12 weeks prior to Screening.
Participants who are currently taking antifibrotic medication (nintedanib, pirfenidone, nerandomilast) approved for IPF should be on a stable dose for at least 6 weeks prior to the Baseline Visit.

Exclusion

Clinical diagnosis or clinical suspicion of an upper or lower respiratory tract infection in the last 8 weeks prior to the Screening visit or during Screening.
Hospitalization for any respiratory illness (including acute exacerbation of IPF) within 2 months prior to Screening.

What this trial measures

  • Relative Change from Baseline in 24-hour Cough Frequency at Week 26Baseline, Week 26